Newsletters

Join us February 1 at Photonics West in San Francisco, CA for a panel workshop dedicated to financing life science and healthcare businesses. The panel's expertise crosses early to late stage venture capital and private equity, strategic corporate investing, licensing, venture debt, and crowd sourcing. Discussions will be around financing and exit strategies - as well as micro and macro trends influencing competition for capital and valuations.

The market for private placements in development stage and high growth photonics businesses is robust. In 2012, a reported $16 billion went to work commercializing technology and scaling businesses with core enabling technology in photonics. In the first half of 2013, more than 450 investments in the same segments are topping $8 billion.

Ceres will publish a market report on current valuations of businesses and product lines that address biophotonics technologies.

The trend of small and middle market consolidation in the highly fragmented photonics industry, as well as in the vertical market segments it enables, persists. Given uncertainty around the future role of government regulation and fiscal policy, and better than expected first quarter US corporate earnings accompanied by weak revenue growth, it is likely that organic growth will remain muted and strategic buyers will continue to absorb targets – sustaining the pattern of consolidation through 2013.

Understanding today's expected rate of return for private capital from angel and venture capital investors to asset based lenders, premiums paid by strategic buyers, and industry dynamics help business valuation professionals advise clients in making better investing, financing, and buy/sell decisions.

Understanding today's expected rate of return for private capital from angel and venture capital investors to asset based lenders, premiums paid by strategic buyers, and industry dynamics help business valuation professionals advise clients in making better investing, financing, and buy/sell decisions.

CERES is actively working with multiple sell-side clients on divestutures to strategic buyers in the markets of optical components, thin film coatings, analytical and clinical instrumentation, and not destructive testing equipment. Please contact Ceres Technology Advisors for more information on these opportunities or if you would like to be notified when new opportunities arise.